Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
Pliant terminates lung disease trial due to adverse events
Since the discontinuation was announced this morning, Pliant’s stock has halved.
Gabrielle Masson
Mar 3, 2025 11:30am
Boehringer widens fibrosis drug's potential after 2nd ph. 3 win
Feb 10, 2025 10:42am
Pliant pauses lung fibrosis trial on advice of safety committee
Feb 10, 2025 4:18am
Eli Lilly to pay Mediar $99M for pulmonary fibrosis prospect
Jan 10, 2025 8:35am
Tvardi to go public via merger with cash-strapped Cara
Dec 18, 2024 10:37am
PureTech's lung fibrosis drug slows decline in phase 2 trial
Dec 16, 2024 7:00am
